Table 2.
Demographic, clinical, and neuropathological characteristics by PART versus Alzheimer’s disease at baseline visit
| Characteristic | PART | AD | P-value |
|---|---|---|---|
| Sample size | 126 | 452 | |
| Number of visits, mean (SD) | 4.5 (2.2) | 4.9 (2.2) | 0.047 |
| Follow up years, mean (SD) | 4.0 (2.5) | 4.6 (2.4) | 0.03 |
| Years between visits, mean (SD) | 1.2 (0.4) | 1.2 (0.5) | 0.62 |
| Mode of onset of cognitive symptomsa, n (%) | <0.001 | ||
| No impairment in cognition | 28 (22.6) | 21 (4.7) | |
| Gradual | 89 (71.8) | 414 (92.0) | |
| Subacute | 3 (2.4) | 7 (1.6) | |
| Abrupt | 3 (2.4) | 8 (1.8) | |
| Other | 1 (0.8) | 0 (0.0) | |
| Age, onset of cognitive decline, mean (SD) | 79.8 (13.4) | 75.8 (11.3) | 0.007 |
| Age, at baseline visit, mean (SD) | 80.1 (11.6) | 78.2 (10.0) | 0.09 |
| Age, at last UDS visit, mean (SD) | 85.4 (12.2) | 83.3 (10.1) | 0.09 |
| Age, at death, mean (SD) | 86.1 (12.2) | 84.1 (10.1) | 0.09 |
| Male sex, n (%) | 68 (54.0) | 231 (51.1) | 0.57 |
| Education, mean (SD) | 15.2 (2.7) | 15.6 (3.0) | 0.11 |
| Non-white race, n (%) | 8 (6.4) | 24 (5.4) | 0.65 |
| Braak stage, n (%) | <0.001 | ||
| None | 16 (12.9) | 0 (0.0) | |
| I | 28 (22.6) | 5 (1.1) | |
| II | 43 (34.7) | 26 (5.8) | |
| III | 13 (10.5) | 36 (8.0) | |
| IV | 23 (18.6) | 73 (16.2) | |
| V | 0 (0.0) | 125 (27.7) | |
| VI | 1 (0.8) | 187 (41.4) | |
| Thal phaseb, n (%) | <0.001 | ||
| None | 40 (56.3) | 0 (0.0) | |
| 1 | 11 (15.5) | 3 (1.3) | |
| 2 | 6 (8.5) | 11 (4.8) | |
| 3 | 7 (9.9) | 38 (16.5) | |
| 4 | 4 (5.6) | 66 (28.6) | |
| 5 | 3 (4.2) | 113 (48.9) | |
| APOE ε4 carrier, n (%) | 16 (13.7) | 204 (48.8) | <0.001 |
| Family history of cognitive impairment, n (%) | 50 (43.5) | 256 (62.0) | <0.001 |
| History of stroke, n (%) | 21 (17.1) | 35 (7.8) | 0.002 |
| History of hypertension, n (%) | 85 (69.7) | 244 (54.3) | 0.002 |
| History of depression, n (%) | 45 (36.0) | 164 (36.8) | 0.87 |
| History of diabetes, n (%) | 21 (17.2) | 34 (7.6) | 0.001 |
| History of traumatic brain injury, n (%) | 13 (10.7) | 53 (11.8) | 0.72 |
| Vascular brain injury at autopsyc, n (%) | 60 (47.6) | 161 (35.8) | 0.02 |
a
P-value for Fisher’s exact test reported because 40% of the cells have expected counts <5. Mode of onset is assessed in a different manner from CDR global score, being based on the clinician judgement of symptoms.
b
Thal phase was not assessed in 43.7% of PART and 48.9% of Alzheimer’s disease participants.
c
Vascular brain injury is a binary variable that includes the presence of haemorrhage, microbleed, infarct/lacune, or microinfarct.
AD = Alzheimer’s disease; SD = standard deviation.